Premium
An adjustable continence therapy device for treating incontinence after prostatectomy: a minimum 2‐year follow‐up
Author(s) -
Gilling Peter J.,
Bell Deborah F.,
Wilson Liam C.,
Westenberg Andre M.,
Reuther Rana,
Fraundorfer Mark R.
Publication year - 2008
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2008.07816.x
Subject(s) - medicine , prostatectomy , balloon , adverse effect , perioperative , urinary incontinence , enucleation , surgery , quality of life (healthcare) , stress incontinence , urology , prostate , cancer , nursing
OBJECTIVE To evaluate the efficacy and safety of the ProACT TM (Uromedica, Inc., MN, USA) balloon device, an alternative for the surgical management of incontinence after prostatectomy. PATIENTS AND METHODS The initial patients who received this device at our institution were evaluated, using urodynamics at baseline and at 6 months. Perioperative variables were recorded and pad usage, volume adjustments, an estimate of Incontinence Quality of Life (I‐QoL) and adverse events were recorded at baseline, and 1, 3, 6, 12 and 24 months after surgery. RESULTS In all, 37 patients were treated on this protocol between November 2001 and March 2005. Of these, 30 had had radical prostatectomy and seven holmium laser enucleation of the prostate. The mean (range) pad usage decreased from 2.81 (1–12) at baseline to 0.7 (0–4) pads at 24 months, and the I‐QOL increased from 49.7 (4.5–77) to 81.3 (13.6–100) over the same period. At 24 months, 62% of 34 men were pad‐free and 81% required one pad or less. Bilateral explantation was required in three patients (11%) for infection (one) and balloon migration (two). All other adverse events were mild and transient. CONCLUSIONS The ProACT balloon device is an acceptable therapy for the surgical management of incontinence after prostatectomy.